82.92
1.99 (2.46%)
Previous Close | 80.93 |
Open | 80.81 |
Volume | 797,252 |
Avg. Volume (3M) | 1,494,807 |
Market Cap | 2,782,919,424 |
Price / Earnings (TTM) | 87.28 |
Price / Earnings (Forward) | 64.52 |
Price / Sales | 7.10 |
Price / Book | 13.17 |
52 Weeks Range | |
Earnings Date | 28 Oct 2024 |
Profit Margin | 8.14% |
Operating Margin (TTM) | 3.61% |
Diluted EPS (TTM) | 0.930 |
Quarterly Revenue Growth (YOY) | 63.70% |
Total Debt/Equity (MRQ) | 246.83% |
Current Ratio (MRQ) | 8.20 |
Operating Cash Flow (TTM) | 23.72 M |
Levered Free Cash Flow (TTM) | -240.13 M |
Return on Assets (TTM) | 2.84% |
Return on Equity (TTM) | 19.41% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Mixed | Mixed |
Medical Devices (Global) | Mixed | Mixed | |
Stock | TransMedics Group, Inc. | Bearish | Bullish |
Stockmoo Score
Analyst Consensus | 2.0 |
Insider Activity | -2.5 |
Price Volatility | 2.0 |
Technical Moving Averages | 1.0 |
Technical Oscillators | -2.5 |
Average | 0.00 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Growth |
% Held by Insiders | 3.20% |
% Held by Institutions | 107.19% |
Ownership
Name | Date | Shares Held |
---|---|---|
Driehaus Capital Management Llc | 30 Sep 2024 | 1,442,207 |
Credit Suisse Ag/ | 31 Mar 2024 | 847,885 |
Fil Ltd | 30 Sep 2024 | 781,397 |
Eventide Asset Management, Llc | 30 Sep 2024 | 690,632 |
Allspring Global Investments Holdings, Llc | 30 Sep 2024 | 599,116 |
52 Weeks Range | ||
Price Target Range | ||
High | 180.00 (Piper Sandler, 117.08%) | Buy |
Median | 120.00 (44.72%) | |
Low | 104.00 (Canaccord Genuity, 25.42%) | Buy |
Average | 129.14 (55.74%) | |
Total | 7 Buy | |
Avg. Price @ Call | 86.62 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Canaccord Genuity | 20 Nov 2024 | 104.00 (25.42%) | Buy | 82.92 |
29 Oct 2024 | 109.00 (31.45%) | Buy | 88.50 | |
TD Cowen | 18 Nov 2024 | 120.00 (44.72%) | Buy | 80.93 |
Baird | 29 Oct 2024 | 150.00 (80.90%) | Buy | 88.50 |
24 Sep 2024 | 200.00 (141.20%) | Buy | 156.00 | |
JP Morgan | 29 Oct 2024 | 116.00 (39.89%) | Buy | 88.50 |
Needham | 29 Oct 2024 | 109.00 (31.45%) | Buy | 88.50 |
23 Aug 2024 | 208.00 (150.84%) | Buy | 175.66 | |
Oppenheimer | 29 Oct 2024 | 125.00 (50.75%) | Buy | 88.50 |
Piper Sandler | 29 Oct 2024 | 180.00 (117.08%) | Buy | 88.50 |
07 Oct 2024 | 180.00 (117.08%) | Buy | 134.11 | |
Show more |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
KHAYAL TAMER I | - | 89.11 | -1,458 | -129,922 |
Aggregate Net Quantity | -1,458 | |||
Aggregate Net Value ($) | -129,922 | |||
Aggregate Avg. Buy ($) | - | |||
Aggregate Avg. Sell ($) | 89.11 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
KHAYAL TAMER I | Officer | 11 Nov 2024 | Automatic sell (-) | 1,458 | 89.11 | 129,922 |
KHAYAL TAMER I | Officer | 11 Nov 2024 | Option execute | 1,458 | - | - |
Date | Type | Details |
---|---|---|
19 Nov 2024 | Announcement | TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference |
29 Oct 2024 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
28 Oct 2024 | Announcement | TransMedics Reports Third Quarter 2024 Financial Results |
15 Oct 2024 | Announcement | TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024 |
27 Sep 2024 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
26 Sep 2024 | Announcement | The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600 |
21 Aug 2024 | Announcement | TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |